Investigating how a protein affects blood vessel cell behavior in heart disease
Nuclear FAK-mediated VSMC differentiation via epigenetic reprograming invascular diseases
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11051862
This study is looking at how certain cells in your blood vessels change when atherosclerosis develops, and it’s specifically checking out a protein that might help us find new ways to treat heart disease and keep your heart healthy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11051862 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how vascular smooth muscle cells (VSMCs) change their behavior during the progression of atherosclerosis, a condition that can lead to heart disease. The study examines the role of a protein called focal adhesion kinase (FAK) in these changes, particularly how it influences the cells' ability to contract and produce important substances. By exploring the molecular mechanisms involved, the research aims to identify potential therapeutic targets that could help stabilize atherosclerotic lesions and improve cardiovascular health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for atherosclerosis or those already diagnosed with cardiovascular diseases.
Not a fit: Patients with non-atherosclerotic cardiovascular conditions or those without any cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reverse the progression of atherosclerosis, ultimately reducing the risk of heart attacks and strokes.
How similar studies have performed: Previous research has shown promising results in targeting similar molecular pathways in cardiovascular diseases, suggesting that this approach may be effective.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIM, STEVE — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: LIM, STEVE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.